Welcome to our dedicated page for Baird Medical SEC filings (Ticker: BDMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Baird Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Baird Medical's regulatory disclosures and financial reporting.
Baird Medical Investment Holdings Limited filed its annual Form 20-F as a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. The report highlights that dividends and cash movements depend heavily on these subsidiaries and are subject to PRC foreign exchange and reserve restrictions.
The company details extensive PRC regulatory licensing for its Class III microwave ablation equipment and needles and a Class II biopsy needle, plus a Manufacture License for Class II and III medical devices valid to May 24, 2026. It discusses reliance on a concentrated distributor and customer base, third-party suppliers, and marketing service providers.
Key risks include evolving PRC healthcare regulation, the Holding Foreign Companies Accountable Act and possible Nasdaq delisting if PCAOB access is lost, prior compliance issues such as a lapsed manufacturing license and underpaid social insurance, dependence on tender processes and medical insurance reimbursement, and challenges in product development, clinical trials, and competition.
Baird Medical Investment Holdings Limited filed its annual Form 20-F as a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. The report highlights that dividends and cash movements depend heavily on these subsidiaries and are subject to PRC foreign exchange and reserve restrictions.
The company details extensive PRC regulatory licensing for its Class III microwave ablation equipment and needles and a Class II biopsy needle, plus a Manufacture License for Class II and III medical devices valid to May 24, 2026. It discusses reliance on a concentrated distributor and customer base, third-party suppliers, and marketing service providers.
Key risks include evolving PRC healthcare regulation, the Holding Foreign Companies Accountable Act and possible Nasdaq delisting if PCAOB access is lost, prior compliance issues such as a lapsed manufacturing license and underpaid social insurance, dependence on tender processes and medical insurance reimbursement, and challenges in product development, clinical trials, and competition.
Baird Medical Investment Holdings Ltd director Xu Lijian filed an initial statement of beneficial ownership. The filing reports direct ownership of 25,000 RSU Shares (BDMD), indicating Xu’s equity position in the company through restricted stock unit shares.
Baird Medical Investment Holdings Ltd director Xu Lijian filed an initial statement of beneficial ownership. The filing reports direct ownership of 25,000 RSU Shares (BDMD), indicating Xu’s equity position in the company through restricted stock unit shares.
Baird Medical Investment Holdings Ltd director Qiu Quan has filed an initial Form 3, formally registering as a reporting person for BDMD. The structured data shows no reported purchases, sales, or other transactions and no derivative positions in this initial ownership statement.
Baird Medical Investment Holdings Ltd director Qiu Quan has filed an initial Form 3, formally registering as a reporting person for BDMD. The structured data shows no reported purchases, sales, or other transactions and no derivative positions in this initial ownership statement.
Baird Medical Investment Holdings Ltd submitted a Form 3 identifying Lu Rongjian as an officer of the company with the title Chief Technical Officer. The structured data shows no reported share transactions, derivative positions, or holding entries associated with this reporting person in this filing.
Baird Medical Investment Holdings Ltd submitted a Form 3 identifying Lu Rongjian as an officer of the company with the title Chief Technical Officer. The structured data shows no reported share transactions, derivative positions, or holding entries associated with this reporting person in this filing.
Baird Medical Investment Holdings Ltd director Gabrielle Bilciu-Wolfson has filed an initial Form 3 disclosing her stake in the company. She reports beneficial ownership of 20,000 shares of Baird Medical common stock, held directly, with no specific buy or sell transaction indicated in this filing.
Baird Medical Investment Holdings Ltd director Gabrielle Bilciu-Wolfson has filed an initial Form 3 disclosing her stake in the company. She reports beneficial ownership of 20,000 shares of Baird Medical common stock, held directly, with no specific buy or sell transaction indicated in this filing.
Baird Medical Investment Holdings Ltd filed an initial insider ownership report for Li Jie Clara, who serves as Acting Chief Financial Officer. This Form 3 excerpt lists her as a reporting person but shows no reported transactions or derivative positions in the summarized data.
Baird Medical Investment Holdings Ltd filed an initial insider ownership report for Li Jie Clara, who serves as Acting Chief Financial Officer. This Form 3 excerpt lists her as a reporting person but shows no reported transactions or derivative positions in the summarized data.
Baird Medical Investment Holdings Ltd director Ragan Joseph Douglas III filed an initial Form 3 reporting his holdings in the company. The filing shows direct ownership of 57,180 BDMD shares, establishing his starting equity position as a reporting insider, with no specific buy or sell transaction disclosed.
Baird Medical Investment Holdings Ltd director Ragan Joseph Douglas III filed an initial Form 3 reporting his holdings in the company. The filing shows direct ownership of 57,180 BDMD shares, establishing his starting equity position as a reporting insider, with no specific buy or sell transaction disclosed.
Baird Medical Investment Holdings Ltd director Hou Wei reported initial holdings of 91,545 RSU Shares (BDMD) in a Form 3 filing. These RSU shares are listed as directly owned, and the filing records Hou Wei’s beneficial ownership position without reporting any specific buy or sell transactions.
Baird Medical Investment Holdings Ltd director Hou Wei reported initial holdings of 91,545 RSU Shares (BDMD) in a Form 3 filing. These RSU shares are listed as directly owned, and the filing records Hou Wei’s beneficial ownership position without reporting any specific buy or sell transactions.
Baird Medical Investment Holdings Limited reported a change in its independent auditor. The company dismissed Kreit & Chiu CPA LLP and appointed Guangdong Prouden CPAs GP as its new independent registered public accounting firm, effective February 10, 2026, for the year ended December 31, 2025.
Kreit & Chiu’s prior reports for the year ended December 31, 2024 contained no adverse opinions or qualifications, and the company states there were no disagreements on accounting, disclosure, or audit scope. However, the company continues to have material weaknesses in internal control over financial reporting, including insufficient U.S. GAAP/SEC-experienced staff and the absence of a comprehensive U.S. GAAP accounting policy manual and documented controls. The new auditor is aware these material weaknesses are considered a reportable event.
Baird Medical Investment Holdings Limited reported a change in its independent auditor. The company dismissed Kreit & Chiu CPA LLP and appointed Guangdong Prouden CPAs GP as its new independent registered public accounting firm, effective February 10, 2026, for the year ended December 31, 2025.
Kreit & Chiu’s prior reports for the year ended December 31, 2024 contained no adverse opinions or qualifications, and the company states there were no disagreements on accounting, disclosure, or audit scope. However, the company continues to have material weaknesses in internal control over financial reporting, including insufficient U.S. GAAP/SEC-experienced staff and the absence of a comprehensive U.S. GAAP accounting policy manual and documented controls. The new auditor is aware these material weaknesses are considered a reportable event.